This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BERKELEY HEIGHTS, N.J., April 3, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced that two abstracts highlighting clinical and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for an oral presentation during a Clinical Trials symposium and a poster presentation at the American Association for Cancer Research (AACR) annual meeting, being held April 6-10, 2013, at the Walter E. Washington Convention Center in Washington, DC.
Details for the presentations are as follows:
Responses to sequential sapacitabine and seliciclib in patients with BRCA-deficient solid tumors
Tuesday, Apr 09, 2013, 2:00 PM - 2:20 PM
Clinical Pharmacology of Novel Agents in Solid Tumors (Clinical Trials Symposium)
Geoffrey I. Shapiro, John Hilton, James M. Cleary, Sara M. Tolaney, Leena Ghandi, Eunice L. Kwak, Jeffrey W. Clark, Andrew Wolanski, Tracy Bell, John Schulz, Sheelagh Frame, Chiara Saladino, Morag Hogben, Scott J. Rodig, Judy H. Chiao, David Blake. Dana-Farber Cancer Institute, Boston, MA, Massachusetts General Hospital, Boston, MA, Cyclacel Ltd, Dundee, United Kingdom, Brigham and Women's Hospital, Boston, MA.
Mechanism of cell death induced by the DNA strand-breaking nucleoside analogue CNDAC
Tuesday, Apr 09, 2013, 8:00 AM - 12:00 PM
Hall A-C, Poster Section 43, Poster Board Number: 13
Targeting Cell Cycle and DNA Damage
Xiaojun Liu, Billie Nowak, Yingjun Jiang, Walter Hittelman, William Plunkett. UT MD Anderson Cancer Center, Houston, TX.